RxDoctor Payments Data

Rosa Rodriguez-Salazar, NP

Family · Charlotte, NCNPI 1760148001

Payments from drug & device makers

$610in general payments, 2019–2025

Across 34 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$235
  • Astellas Pharma US Inc$163
  • Otsuka America Pharmaceutical, Inc.$53
  • AbbVie$43
  • Sumitomo Pharma America, Inc.$42
  • Alkermes, Inc.$22
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$59097%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$610 in reported general payments places this provider in the 60th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$14,684
Medicare patients
72
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$66,703
JardianceEmpagliflozin154$49,728
Invega SustennaPaliperidone Palmitate15$37,158
MyrbetriqMirabegron233$36,551
Risperdal ConstaRisperidone Microspheres15$24,139
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$24,133
OzempicSemaglutide18$18,411
JanuviaSitagliptin Phosphate28$13,473
Tresiba Flextouch U-100Insulin Degludec26$12,246
Breo ElliptaFluticasone/Vilanterol28$12,014
GemtesaVibegron29$11,325
LinzessLinaclotide16$10,993
NeuproRotigotine12$10,732
Incruse ElliptaUmeclidinium Bromide22$8,187
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc77$7,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$163$36,551233 claims
Sumitomo Pharma America, Inc.Gemtesa$42$11,32529 claims
AbbVieLinzess$43$10,99316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,522 family providers in North Carolina.

Other family in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →